252 related articles for article (PubMed ID: 24206261)
1. Should ANVISA be permitted to reject pharmaceutical patent applications in Brazil?
Mueller LL; Taketsuma Costa SM
Expert Opin Ther Pat; 2014 Jan; 24(1):1-4. PubMed ID: 24206261
[TBL] [Abstract][Full Text] [Related]
2. Pharmaceutical patent term extension and patent prosecution in Brazil (1997-2018).
Mercadante E; Paranhos J
Cad Saude Publica; 2022; 38(1):e00043021. PubMed ID: 35107507
[TBL] [Abstract][Full Text] [Related]
3. Update on Brazil's pharma patent landscape.
Gosain R
Pharm Pat Anal; 2016 Sep; 5(6):385-390. PubMed ID: 27804784
[TBL] [Abstract][Full Text] [Related]
4. The consequences of 'double examination' for pharmaceutical patent applications in Brazil.
Salerno G
Pharm Pat Anal; 2017 Mar; 6(2):49-51. PubMed ID: 28274178
[No Abstract] [Full Text] [Related]
5. Asserting the primacy of health over patent rights: a comparative study of the processes that led to the use of compulsory licensing in Thailand and Brazil.
Rosenberg ST
Dev World Bioeth; 2014 Aug; 14(2):83-91. PubMed ID: 24750542
[TBL] [Abstract][Full Text] [Related]
6. Main Reasons for Registration Application Refusal of Generic and Similar Pharmaceutical Drug Products by the Brazilian Health Regulatory Agency (ANVISA).
do Carmo AC; Piras SS; Rocha NF; Gratieri T
Biomed Res Int; 2017; 2017():7894937. PubMed ID: 28280742
[No Abstract] [Full Text] [Related]
7. [How much does the backlog on drug patents cost for health in Brazil?].
Jannuzzi AHL; Vasconcellos AG
Cad Saude Publica; 2017 Aug; 33(8):e00206516. PubMed ID: 28832788
[TBL] [Abstract][Full Text] [Related]
8. [Specificities of patent protection in the pharmaceutical industry: modalities and traits of intellectual property].
Jannuzzi AH; Vasconcellos AG; de Souza CG
Cad Saude Publica; 2008 Jun; 24(6):1205-18. PubMed ID: 18545747
[TBL] [Abstract][Full Text] [Related]
9. The political contradictions of incremental innovation: lessons from pharmaceutical patent examination in Brazil.
Shadlen KC
Polit Soc; 2011; 39(2):143-74. PubMed ID: 21913365
[TBL] [Abstract][Full Text] [Related]
10. US files WTO complaints against Brazil over requirement for "local working" of patents.
Elliott R
Can HIV AIDS Policy Law Rev; 2000; 5(4):28. PubMed ID: 11833162
[TBL] [Abstract][Full Text] [Related]
11. How do public health safeguards in Indian patent law affect pharmaceutical patenting in practice?
Sampat BN; Amin T
J Health Polit Policy Law; 2013 Aug; 38(4):735-55. PubMed ID: 23645877
[TBL] [Abstract][Full Text] [Related]
12. Will the Modi government succumb to US and industry pressure to modify its pro-access pharmaceutical patent policy?
Baker BK
Expert Opin Ther Pat; 2015 Jun; 25(6):625-8. PubMed ID: 25704359
[TBL] [Abstract][Full Text] [Related]
13. The need for balancing the regulation of pharmaceutical trademarks between the Food and Drug Administration and the Patent and Trademark Office.
Boring D; Doninger C
Food Drug Law J; 1997; 52(1):109-16. PubMed ID: 10346714
[No Abstract] [Full Text] [Related]
14. Expedited pharma patenting in Brazil.
Moreira P
Pharm Pat Anal; 2019 Mar; 8(2):51-59. PubMed ID: 30887881
[TBL] [Abstract][Full Text] [Related]
15. [The Brazilian pharmaceutical market and the North American war effort].
Quintaneiro T
Estud Hist; 2002; (29):141-64. PubMed ID: 18030707
[No Abstract] [Full Text] [Related]
16. Drug patent protection: how long is long enough?
Sibbald B
CMAJ; 2001 May; 164(9):1331. PubMed ID: 11341146
[No Abstract] [Full Text] [Related]
17. EU court gets tough on patent extensions for combo products.
Waters H
Nat Med; 2012 Jan; 18(1):4. PubMed ID: 22227647
[No Abstract] [Full Text] [Related]
18. The Regulatory Pathway for Advanced Cell Therapy and Gene Therapy Products in Brazil: A Road to Be Built.
de Freitas DR
Adv Exp Med Biol; 2015; 871():213-9. PubMed ID: 26374221
[TBL] [Abstract][Full Text] [Related]
19. Health policy or intellectual property policy? The fight over Bill C-91. Canadian Healthcare Association.
Int J Health Care Qual Assur Inc Leadersh Health Serv; 1997; 10(2-3):vii-x. PubMed ID: 10169229
[TBL] [Abstract][Full Text] [Related]
20. The new patent regime and disease priorities in India.
Gupta I; Guin P; Trivedi M
Glob Public Health; 2013; 8(1):37-54. PubMed ID: 22845021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
